15 Days Price Change
Closing In
WEBSITE Inc. Year: 2017 Industry: Pharmaceuticals & Drugs Listed Page
Buy unlisted shares early and participate in the growth before public listing.
Face Value 10 per share
Price 372 to 391 per share
P/E (x) 24.3
Sales( Cr.) 398
PAT( Cr.) 58
EPS 16.1
Draft Prospectus --
Exchange BSE-NSE
Company Promoters
Pre Issue Share Holding 71.1%
Post Issue Share Holding --%
Listing Price: 593.7
Listing Gain: 34.14%
Current Price: 1120.7
Gain On Issue: 1120.7 | 0%
GMP: --
GMP %: -- %
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | 14,858 |
| Retail (Max) | 13 | 494 | 193,154 |
| S-HNI (Min) | 14 | 532 | 208,012 |
| S-HNI (Max) | 67 | 2546 | 995,486 |
| B-HNI (Min) | 68 | 2584 | 1,010,344 |
1. Investment in one of the Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility. 2. Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company. 3. Investment in the Subsidiary, namely, Havix, for repayment/pre-payment in whole or part of certain borrowings availed by such Subsidiary. 4. Funding the working capital requirements of the Company. 5. Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements. 6. Funding inorganic growth through acquisition and other strategic initiatives.
| Category | Nos | Bid | Bid (x) |
|---|---|---|---|
| QIB | 11165792 | 1092461089 | 97.8x |
| NII | 2233158 | 224097405 | 100.3x |
| Retail | 1488772 | 138694000 | 93.2x |
| EMP | 0 | 0 | 0x |
| Total | 14887723 | 1456912573 | 97.9x |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 85% | 205% | 0% | 0% |
| Operating Profit CAGR | 148% | 279% | 0% | 0% |
| PAT CAGR | 76% | 287% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 116% | NA% | NA% | NA% |
| ROE Average | 12% | 20% | 15% | 15% |
| ROCE Average | 12% | 14% | 12% | 12% |
Senores Pharmaceuticals Ltd.
1101 To 1103, 11th Floor, South Tower One 42 Opp. Jayantilal Park Ambali Bopal Road
Senores Pharmaceuticals Ltd.
Equirus Capital Pvt Ltd
Nuvama Wealth Management Ltd.
Ambit Private Limited
Senores Pharmaceuticals Ltd.
When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.
For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.
Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.
Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.
Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.
ChatGPT
Claude
Perplexity
